stockrowExelixis, Inc.
EXEL Healthcare Biotechnology
Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024.
- Revenue
- +10.2%
- EPS
- +22.2%
- Free cash flow
- −4.83%
Quarter to September 2026, against a year earlier
Follow EXEL
Alert me
Exelixis, Inc. (EXEL) Shares outstanding
Exelixis, Inc.'s shares outstanding at the end of fiscal 2025 was $281.9M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $255.8M. Over the past ten years it has ranged from $209.2M (fiscal 2015) to $324.6M (fiscal 2022); the current reading is higher than 27% of that period. Exelixis, Inc. ranks 28th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $281.9M | (4.82%) |
| FY2024 | $296.1M | (7.88%) |
| FY2023 | $321.5M | (0.95%) |
| FY2022 | $324.6M | 0.68% |
| FY2021 | $322.4M | 1.37% |
| FY2020 | $318.0M | 0.95% |
| FY2019 | $315.0M | 0.71% |
| FY2018 | $312.8M | 0.26% |
| FY2017 | $312.0M | 24.54% |
| FY2016 | $250.5M | 19.74% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $255.8M | (1.51%) |
| Jun 2026 | $259.7M | (2.86%) |
| Mar 2026 | $267.3M | (5.16%) |
| Dec 2025 | $281.9M | 1.19% |
| 43 more quarters | Free account |
Against its own ten years
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| SMMT Summit Therapeutics PLC compare | $778.2M |
| EXEL Exelixis, Inc. | $255.8M |
| BNTX BioNTech SE Sponsored ADR compare | $252.7M |
| INSM Insmed, Inc. compare | $218.8M |
| BBIO BridgeBio Pharma, Inc. compare | $196.0M |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $138.0M |
| HALO Halozyme Therapeutics, Inc. compare | $122.6M |
| ASND Ascendis Pharma A/S compare | $68.3M |
| JAZZ Jazz Pharmaceuticals PLC compare | $64.7M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item
More on EXEL
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement